The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells - Wikidata - wikimedia - TriplyDB

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

http://www.wikidata.org/entity/Q24519206

about

The role of microRNA genes in papillary thyroid carcinoma Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer Targeting BRAF in thyroid cancer Tumor-Associated Mast Cells in Thyroid Cancer AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines BRAF activates and physically interacts with PAK to regulate cell motility BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications Protein kinase A and B-Raf mediate extracellular signal-regulated kinase activation by thyrotropin Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment.The role of podoplanin in the biology of differentiated thyroid cancers.A cascade of modules of a network defines cancer progression Association of microRNA-related gene XPO5 rs11077 polymorphism with susceptibility to thyroid cancer.Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer Prognostic utility of BRAF mutation in papillary thyroid cancer.Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.Multi-targeted approach in the treatment of thyroid cancer.Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts.TNFα-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines.Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report.Immune response in thyroid cancer: widening the boundaries.Molecular pathogenesis and mechanisms of thyroid cancer Novel approaches in anaplastic thyroid cancer therapy Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma.Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy.Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein Mouse models of follicular and papillary thyroid cancer progression.Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma.The Effects of Hashimoto Thyroiditis on Lymph Node Metastases in Unifocal and Multifocal Papillary Thyroid Carcinoma: A Retrospective Chinese Cohort Study Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines.BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

P2860

Q24535848-FF6A22EB-86AA-40C1-A972-1CEA182FDDC2 Q24652758-665FFEF4-6AB4-4D6A-B2AF-B742F1570157 Q24653496-0229705F-0725-4E52-A931-7C5AA281B40B Q26784415-875FAD7C-FF37-4097-ACB4-78CB62B75147 Q27851932-916FB84D-2ABA-4942-B275-3259D01BF2D5 Q28248127-6C95B8AE-6158-4211-BD2A-069FF3262E48 Q28543370-4C4058F9-2173-4562-9896-A2FACFD9C98A Q28569443-B3E5EA8F-1BA0-4A6D-864C-6BD6E378ADB3 Q28584124-4FF3845D-E0B9-4749-ACA8-300A70A9C1AF Q33357290-A9701240-E891-4B1F-9AF1-C6A381B673E6 Q33363441-87D778AD-4664-4B77-BA0C-49FD9414CE54 Q33568168-B3827955-CA5C-4B6A-8735-08D93AFBF438 Q33574838-D86E4EB0-FF9B-472B-B9FC-11166821CD62 Q33621219-1AAFA6A5-94FF-48D7-B309-5164681BCCC3 Q33691759-84B97AB7-A280-4947-AFA4-BA9C512E8DFF Q33770842-4BD86913-4C18-4D83-B686-33F479E88E71 Q33771120-81D9A848-AB07-4385-9B38-51E290D26157 Q33931450-3F72C8FA-2A88-4CAB-8D90-5BC1EBD26F12 Q33982413-9E7096F3-3400-407A-ACFE-F552A8C57B4A Q34078370-22DD5C96-213A-490C-A48F-857D12D620CD Q34145178-85365C31-9E4E-4468-A0CD-676E757A42B4 Q34155350-951AEFF2-81D1-4B7D-9946-C68BEE67EFCA Q34298364-FA1F1877-F57F-4804-93EA-998474D6C950 Q34310495-2C575B35-8E62-4267-97EB-4196992F92C8 Q34329018-623E7376-B90C-4E4C-B6A7-50E2FC2EE066 Q34458018-66C3682E-2E33-48D8-810C-99C374D87F25 Q34544846-DF1336A8-9434-4CF3-ACB1-E6E67EAC4528 Q34662980-E4EBD90B-44E5-4824-AF3A-0B8DC38FADEE Q35570953-5D10AF75-3DCD-4C70-B7FF-2680D1D490A3 Q35731026-A7BBABB1-EAAE-414A-9F68-83C998EA3BAA Q35763320-57BC65F9-BEF7-43DE-BF72-14576E7693F1 Q35971896-2D3FD68B-0802-403F-8979-E1E282F9F30C Q35973628-C37DA8EB-FB43-4A6F-ACD6-701E0BC58985 Q35977327-BDE2D4A8-1292-4981-A0C5-4BE043997020 Q35989598-9B1D2F4F-1FCA-48A8-8417-05774ACB8A1E Q36096044-A12CC3D2-F4AB-4133-8E1C-33FF2158C0D9 Q36194098-E5702F1D-B890-4935-9AF0-E3A8587D8733 Q36580921-E99686C5-4B02-4A15-AFF2-E662A9654D1F Q36610272-70EB85A2-D4CD-4BCD-81AA-85C39FAF7409 Q36732681-8F0F6E50-710D-4086-9058-349A475176BE

P2860

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

http://www.wikidata.org/entity/Q24519206

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@ast

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@en

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@en-gb

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@nl

type

label

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@ast

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@en

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@en-gb

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@nl

prefLabel

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@ast

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@en

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@en-gb

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@nl

P1433

Q24519206-BF1F0767-4242-49E7-B8DB-5FA5004C5756

P1476

Q24519206-B9F88880-BF08-42EF-A6B8-A71D6A86C0E9

P2093

Q24519206-95E8B495-EFAF-4B85-B48E-B38548A2097E

Q24519206-99964489-700B-40EE-B0AA-BE3409157E42

Q24519206-9B76C806-4D66-471C-8984-E579A3959EF0

Q24519206-BC1AD9A5-236F-4A38-A44E-D36173895F76

Q24519206-CED36BDB-895B-4987-88ED-BA33C97C5141

Q24519206-E64F8718-952B-41B8-B869-ACCB23951C5B

Q24519206-F896FF19-E3A1-49FA-9796-F31DFC60B88E

P2860

Q24519206-0102D8B0-855D-49CE-A2D9-D20CBCC3CC10

Q24519206-09C5B7E8-9B62-4D51-AD75-8441C9CD437A

Q24519206-0B4285AF-83D5-4C91-B3BE-ED72A6A246B0

Q24519206-0B4C2368-ED68-4492-A2F5-F17855FD2C46

Q24519206-0B6CC20A-86BA-4B6B-A483-29439390421E

Q24519206-0D0B4899-D2F2-476F-AEA7-2DD5A1C46EF9

Q24519206-0FED5372-E3A5-4DFA-9854-8EDD88F78C64

Q24519206-11C11622-BC39-49EE-ACA3-B9CDAA08C3CE

Q24519206-166E9FD5-7F26-4375-BE08-8FE4CCCBA2CF

Q24519206-16B7D81A-EE7A-40B9-8D03-756AEA9FAA54

P304

Q24519206-137D61EC-D533-4384-A5ED-48E97B8B9DB5

P31

Q24519206-6C807910-C573-4510-A214-E7B49E9DCA8A

P3181

Q24519206-679B31E8-7113-4738-9C17-9FCE006E7676

P356

Q24519206-572C016B-98CF-4CE7-95E8-D32F1BB023CD

Q24519206-D13D0563-1852-4451-8FC9-D23F38F58D23

P407

Q24519206-4C26A99E-09E0-41E6-9A2A-E3ABB4AB149D

P433

Q24519206-B71EDEDB-21B5-4866-9F48-69C2383E6E7D

P478

Q24519206-4F1D58E7-D98E-4B0C-844A-20CBDFA45B4F

P50

Q24519206-1CF24EB9-9429-432B-A0AE-6625412B5920

Q24519206-5BC4AAD1-3D50-4E7B-BE19-A357B276D820

Q24519206-83C5326D-D9E2-4025-84AB-83C3517C426A

Q24519206-96D24E23-D02B-4A44-B1FC-796659135321

Q24519206-B345A929-2CB0-4702-B54F-C4D66D8DD445

Q24519206-B8EBCFF7-C237-48E8-8D8E-C3F811FC9731

P577

Q24519206-948E5E5F-5F01-468D-A748-6865657CC607

P698

Q24519206-3C78DF97-DF99-4004-B0E7-C8DB73655628

P932

Q24519206-C79123EF-D344-4660-8A2A-B13ADD929EE3

P3181

P356

P1433

Journal of Clinical Investigation

P1476

The RET/PTC-RAS-BRAF linear si ...... notype of thyroid cancer cells

@en

P2093

Anna Maria Cirafici

http://www.w3.org/2001/XMLSchema#string

Fiorina Caiazzo

http://www.w3.org/2001/XMLSchema#string

Giuliana Salvatore

http://www.w3.org/2001/XMLSchema#string

Massimo Santoro

http://www.w3.org/2001/XMLSchema#string

Mogens Kruhoffer

http://www.w3.org/2001/XMLSchema#string

Torben Orntoft

http://www.w3.org/2001/XMLSchema#string

Valentina Guarino

http://www.w3.org/2001/XMLSchema#string

P2860

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma

Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade

Inflammation and cancer

Mutations of the BRAF gene in human cancer

Inflammation and cancer: back to Virchow?

Mig-6 is a negative regulator of the epidermal growth factor receptor signal

Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7

Identification of RET autophosphorylation sites by mass spectrometry

Chemokines--chemotactic cytokines that mediate inflammation

The microenvironment of the tumour-host interface

P304

1068-1081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4109936

http://www.w3.org/2001/XMLSchema#string

P356

10.1172/JCI200522758

http://www.w3.org/2001/XMLSchema#string

10.1172/JCI22758

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Riccardo Giannini

Rosa Marina Melillo

Valentina De Falco

Maria Domenica Castellone

P577

2005-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15761501

http://www.w3.org/2001/XMLSchema#string

P932

1062891

http://www.w3.org/2001/XMLSchema#string